Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Uprichard

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Viruses|July 27, 2022
Sequencing during Times of Change: Evaluating SARS-CoV-2 Clinical Samples during the Transition from the Delta to Omicron WaveShuchen Feng, Mudassir S Ali, Monika Evdokimova, et al.
Viruses|August 10, 2021
HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection DynamicsKarina Durso-Cain, Peter Kumberger, Yannik Schälte, et al.
Antiviral Research|July 5, 2017
Modeling HCV cure after an ultra-short duration of therapy with direct acting agentsAshish Goyal, Yoav Lurie, Eric G Meissner, et al.
Virology|August 31, 2010
The rate of hepatitis C virus infection initiation in vitro is directly related to particle densityAli Sabahi, Katherine A Marsh, Harel Dahari, et al.
JHEP Reports : Innovation in Hepatology|April 16, 2025
Modeling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytesLouis Shekhtman, Yuji Ishida, Masataka Tsuge, et al.
Viruses|September 28, 2021
Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed PatientsXufang Deng, Monika Evdokimova, Amornrat O'Brien, et al.
Journal of Virology|April 29, 2021
Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric MiceVladimir Reinharz, Yuji Ishida, Masataka Tsuge, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2005
Robust hepatitis C virus infection in vitroJin Zhong, Pablo Gastaminza, Guofeng Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeJeremie Guedj, Harel Dahari, Libin Rong, et al.
World Journal of Hepatology|July 27, 2016
Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case reportYaakov Hasin, Shimon Shteingart, Harel Dahari, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Viruses|July 27, 2022
Sequencing during Times of Change: Evaluating SARS-CoV-2 Clinical Samples during the Transition from the Delta to Omicron WaveShuchen Feng, Mudassir S Ali, Monika Evdokimova, et al.
Viruses|August 10, 2021
HCV Spread Kinetics Reveal Varying Contributions of Transmission Modes to Infection DynamicsKarina Durso-Cain, Peter Kumberger, Yannik Schälte, et al.
Antiviral Research|July 5, 2017
Modeling HCV cure after an ultra-short duration of therapy with direct acting agentsAshish Goyal, Yoav Lurie, Eric G Meissner, et al.
Virology|August 31, 2010
The rate of hepatitis C virus infection initiation in vitro is directly related to particle densityAli Sabahi, Katherine A Marsh, Harel Dahari, et al.
JHEP Reports : Innovation in Hepatology|April 16, 2025
Modeling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytesLouis Shekhtman, Yuji Ishida, Masataka Tsuge, et al.
Viruses|September 28, 2021
Breakthrough Infections with Multiple Lineages of SARS-CoV-2 Variants Reveals Continued Risk of Severe Disease in Immunosuppressed PatientsXufang Deng, Monika Evdokimova, Amornrat O'Brien, et al.
Journal of Virology|April 29, 2021
Understanding Hepatitis B Virus Dynamics and the Antiviral Effect of Interferon Alpha Treatment in Humanized Chimeric MiceVladimir Reinharz, Yuji Ishida, Masataka Tsuge, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2005
Robust hepatitis C virus infection in vitroJin Zhong, Pablo Gastaminza, Guofeng Cheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 23, 2013
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-lifeJeremie Guedj, Harel Dahari, Libin Rong, et al.
World Journal of Hepatology|July 27, 2016
Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case reportYaakov Hasin, Shimon Shteingart, Harel Dahari, et al.
Pageof 6